Vor Biopharma (VOR) vs Windward Bio Group (WWB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Windward Bio Group is the larger company by market cap ($1.45 billion vs $1.18 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VOR | WWB |
|---|---|---|
| Share price | $19.19 | $24.29 |
| Market cap | $1.18B | $1.45B |
| 1-day change | +3.62% | +1.15% |
| YTD return | +46.71% | — |
| 1-year return | +157.58% | — |
| 5-year return | -92.00% | — |
| P/E ratio (TTM) | 0.06 | — |
| EPS (TTM) | $300.56 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-695.98M | — |
| 52-week high | $26.00 | $33.99 |
| 52-week low | $7.21 | $18.35 |
| Distance from 52-week high | -26.19% | -28.55% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +103.23% | — |
| Average volume | 945.67K | 434.33K |
| Shares outstanding | 61.43M | 59.58M |
| Employees | 76 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
About Windward Bio Group
WWB stock →Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees
VOR vs WWB FAQ
Which is bigger, Vor Biopharma or Windward Bio Group?
Windward Bio Group (WWB) is larger, with a market capitalization of $1.45B compared with $1.18B for Vor Biopharma (VOR).
Are Vor Biopharma and Windward Bio Group in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.